As part of the deal, Glycotope will be Cantargia’s production partner to obtain material for the clinical studies of CAN04 in cancer patients.
The deal will also see Glycotope responsible for the development and the Good Manufacturing Practices (GMP) production of CAN04 as well as manufacture the material to be used in both future toxicology studies and clinical trials.
Cantargia CEO Göran Forsberg said: "The collaboration with Glycotope Biotechnology will be a cornerstone in the development of CAN04. We look forward to work with Glycotope Biotechnology."
Glycotope Biotechnology COO Franzpeter Bracht said: "To bring Cantargia’s lead drug candidate into clinical trials will be a great opportunity for Glycotope Biotechnology as Contract Manufacturer for innovative biopharmaceuticals."
Cantargia is focused on developing an antibody-based cancer treatment, which attacks cancer stem cells as well as mature cancer cells.
In preclinical in-vitro and in-vivo trials the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary.